143 related articles for article (PubMed ID: 12965106)
1. Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes.
Lindsay JR; McKillop AM; Mooney MH; O'Harte FP; Flatt PR; Bell PM
Diabetes Res Clin Pract; 2003 Sep; 61(3):167-73. PubMed ID: 12965106
[TBL] [Abstract][Full Text] [Related]
2. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
Mari A; Gastaldelli A; Foley JE; Pratley RE; Ferrannini E
Diabetes Care; 2005 May; 28(5):1132-8. PubMed ID: 15855578
[TBL] [Abstract][Full Text] [Related]
3. Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Hollander PA; Schwartz SL; Gatlin MR; Haas SJ; Zheng H; Foley JE; Dunning BE
Diabetes Care; 2001 Jun; 24(6):983-8. PubMed ID: 11375357
[TBL] [Abstract][Full Text] [Related]
4. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
5. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (A-4166).
Gribble FM; Manley SE; Levy JC
Diabetes Care; 2001 Jul; 24(7):1221-5. PubMed ID: 11423506
[TBL] [Abstract][Full Text] [Related]
6. Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes.
Juurinen L; Tiikkainen M; Saltevo J; Nikkilä K; Lanki H; Leppävuori E; Kock T; Teikari-Myyrä T; Kauppinen-Mäkelin R; Kotronen A; Yki-Järvinen H
Diabet Med; 2009 Apr; 26(4):409-15. PubMed ID: 19388972
[TBL] [Abstract][Full Text] [Related]
7. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
[TBL] [Abstract][Full Text] [Related]
8. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus.
Walter YH; Spratt DI; Garreffa S; McLeod JF
Eur J Clin Pharmacol; 2000 May; 56(2):129-33. PubMed ID: 10877006
[TBL] [Abstract][Full Text] [Related]
9. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Kalbag JB; Walter YH; Nedelman JR; McLeod JF
Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
[TBL] [Abstract][Full Text] [Related]
10. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
Shimabukuro M; Higa N; Takasu N; Tagawa T; Ueda S
Diabet Med; 2004 Sep; 21(9):983-6. PubMed ID: 15317602
[TBL] [Abstract][Full Text] [Related]
11. Nateglinide, a non-sulfonylurea rapid insulin secretagogue, increases pancreatic islet blood flow in rats.
Iwase M; Nakamura U; Uchizono Y; Nohara S; Sasaki N; Sonoki K; Iida M
Eur J Pharmacol; 2005 Aug; 518(2-3):243-50. PubMed ID: 16023099
[TBL] [Abstract][Full Text] [Related]
12. Weight loss-associated changes in acute effects of nateglinide on insulin secretion after glucose loading: results of glucose loading on 2 consecutive days.
Mori Y; Mamori S; Tajima N
Diabetes Obes Metab; 2005 Mar; 7(2):182-8. PubMed ID: 15715891
[TBL] [Abstract][Full Text] [Related]
13. Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus.
Whitelaw DC; Clark PM; Smith JM; Nattrass M
Diabet Med; 2000 Mar; 17(3):225-9. PubMed ID: 10784228
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
15. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
[TBL] [Abstract][Full Text] [Related]
16. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
[TBL] [Abstract][Full Text] [Related]
17. Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control.
Fonseca V; Grunberger G; Gupta S; Shen S; Foley JE
Diabetes Care; 2003 Jun; 26(6):1685-90. PubMed ID: 12766094
[TBL] [Abstract][Full Text] [Related]
18. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes.
Barnett AH; Anderson DM; Shelley S; Morgan R; Owens DR
Diabetes Obes Metab; 2004 Mar; 6(2):104-13. PubMed ID: 14746575
[TBL] [Abstract][Full Text] [Related]
20. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
